Cargando…
In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma
Rationale: Intrinsic brain tumors, such as gliomas are largely resistant to immunotherapies including immune checkpoint blockade. Adoptive cell therapies (ACT) including chimeric antigen receptor (CAR) or T cell receptor (TCR)-transgenic T cell therapy targeting glioma-associated antigens are an eme...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614679/ https://www.ncbi.nlm.nih.gov/pubmed/37908732 http://dx.doi.org/10.7150/thno.87248 |
_version_ | 1785129072811048960 |
---|---|
author | Hunger, Jessica Schregel, Katharina Boztepe, Berin Agardy, Dennis Alexander Turco, Verena Karimian-Jazi, Kianush Weidenfeld, Ina Streibel, Yannik Fischer, Manuel Sturm, Volker Santarella-Mellwig, Rachel Kilian, Michael Jähne, Kristine Sahm, Katharina Wick, Wolfgang Bunse, Lukas Heiland, Sabine Bunse, Theresa Bendszus, Martin Platten, Michael Breckwoldt, Michael O. |
author_facet | Hunger, Jessica Schregel, Katharina Boztepe, Berin Agardy, Dennis Alexander Turco, Verena Karimian-Jazi, Kianush Weidenfeld, Ina Streibel, Yannik Fischer, Manuel Sturm, Volker Santarella-Mellwig, Rachel Kilian, Michael Jähne, Kristine Sahm, Katharina Wick, Wolfgang Bunse, Lukas Heiland, Sabine Bunse, Theresa Bendszus, Martin Platten, Michael Breckwoldt, Michael O. |
author_sort | Hunger, Jessica |
collection | PubMed |
description | Rationale: Intrinsic brain tumors, such as gliomas are largely resistant to immunotherapies including immune checkpoint blockade. Adoptive cell therapies (ACT) including chimeric antigen receptor (CAR) or T cell receptor (TCR)-transgenic T cell therapy targeting glioma-associated antigens are an emerging field in glioma immunotherapy. However, imaging techniques for non-invasive monitoring of adoptively transferred T cells homing to the glioma microenvironment are currently lacking. Methods: Ultrasmall iron oxide nanoparticles (NP) can be visualized non-invasively by magnetic resonance imaging (MRI) and dedicated MRI sequences such as T(2)* mapping. Here, we develop a protocol for efficient ex vivo labeling of murine and human TCR-transgenic and CAR T cells with iron oxide NPs. We assess labeling efficiency and T cell functionality by flow cytometry and transmission electron microscopy (TEM). NP labeled T cells are visualized by MRI at 9.4 T in vivo after adoptive T cell transfer and correlated with 3D models of cleared brains obtained by light sheet microscopy (LSM). Results: NP are incorporated into T cells in subcellular cytoplasmic vesicles with high labeling efficiency without interfering with T cell viability, proliferation and effector function as assessed by cytokine secretion and antigen-specific killing assays in vitro. We further demonstrate that adoptively transferred T cells can be longitudinally monitored intratumorally by high field MRI at 9.4 Tesla in a murine glioma model with high sensitivity. We find that T cell influx and homogenous spatial distribution of T cells within the TME as assessed by T(2)* imaging predicts tumor response to ACT whereas incomplete T cell coverage results in treatment resistance. Conclusion: This study showcases a rational for monitoring adoptive T cell therapies non-invasively by iron oxide NP in gliomas to track intratumoral T cell influx and ultimately predict treatment outcome. |
format | Online Article Text |
id | pubmed-10614679 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-106146792023-10-31 In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma Hunger, Jessica Schregel, Katharina Boztepe, Berin Agardy, Dennis Alexander Turco, Verena Karimian-Jazi, Kianush Weidenfeld, Ina Streibel, Yannik Fischer, Manuel Sturm, Volker Santarella-Mellwig, Rachel Kilian, Michael Jähne, Kristine Sahm, Katharina Wick, Wolfgang Bunse, Lukas Heiland, Sabine Bunse, Theresa Bendszus, Martin Platten, Michael Breckwoldt, Michael O. Theranostics Research Paper Rationale: Intrinsic brain tumors, such as gliomas are largely resistant to immunotherapies including immune checkpoint blockade. Adoptive cell therapies (ACT) including chimeric antigen receptor (CAR) or T cell receptor (TCR)-transgenic T cell therapy targeting glioma-associated antigens are an emerging field in glioma immunotherapy. However, imaging techniques for non-invasive monitoring of adoptively transferred T cells homing to the glioma microenvironment are currently lacking. Methods: Ultrasmall iron oxide nanoparticles (NP) can be visualized non-invasively by magnetic resonance imaging (MRI) and dedicated MRI sequences such as T(2)* mapping. Here, we develop a protocol for efficient ex vivo labeling of murine and human TCR-transgenic and CAR T cells with iron oxide NPs. We assess labeling efficiency and T cell functionality by flow cytometry and transmission electron microscopy (TEM). NP labeled T cells are visualized by MRI at 9.4 T in vivo after adoptive T cell transfer and correlated with 3D models of cleared brains obtained by light sheet microscopy (LSM). Results: NP are incorporated into T cells in subcellular cytoplasmic vesicles with high labeling efficiency without interfering with T cell viability, proliferation and effector function as assessed by cytokine secretion and antigen-specific killing assays in vitro. We further demonstrate that adoptively transferred T cells can be longitudinally monitored intratumorally by high field MRI at 9.4 Tesla in a murine glioma model with high sensitivity. We find that T cell influx and homogenous spatial distribution of T cells within the TME as assessed by T(2)* imaging predicts tumor response to ACT whereas incomplete T cell coverage results in treatment resistance. Conclusion: This study showcases a rational for monitoring adoptive T cell therapies non-invasively by iron oxide NP in gliomas to track intratumoral T cell influx and ultimately predict treatment outcome. Ivyspring International Publisher 2023-09-25 /pmc/articles/PMC10614679/ /pubmed/37908732 http://dx.doi.org/10.7150/thno.87248 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Hunger, Jessica Schregel, Katharina Boztepe, Berin Agardy, Dennis Alexander Turco, Verena Karimian-Jazi, Kianush Weidenfeld, Ina Streibel, Yannik Fischer, Manuel Sturm, Volker Santarella-Mellwig, Rachel Kilian, Michael Jähne, Kristine Sahm, Katharina Wick, Wolfgang Bunse, Lukas Heiland, Sabine Bunse, Theresa Bendszus, Martin Platten, Michael Breckwoldt, Michael O. In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma |
title | In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma |
title_full | In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma |
title_fullStr | In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma |
title_full_unstemmed | In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma |
title_short | In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma |
title_sort | in vivo nanoparticle-based t cell imaging can predict therapy response towards adoptive t cell therapy in experimental glioma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614679/ https://www.ncbi.nlm.nih.gov/pubmed/37908732 http://dx.doi.org/10.7150/thno.87248 |
work_keys_str_mv | AT hungerjessica invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma AT schregelkatharina invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma AT boztepeberin invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma AT agardydennisalexander invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma AT turcoverena invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma AT karimianjazikianush invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma AT weidenfeldina invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma AT streibelyannik invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma AT fischermanuel invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma AT sturmvolker invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma AT santarellamellwigrachel invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma AT kilianmichael invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma AT jahnekristine invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma AT sahmkatharina invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma AT wickwolfgang invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma AT bunselukas invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma AT heilandsabine invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma AT bunsetheresa invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma AT bendszusmartin invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma AT plattenmichael invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma AT breckwoldtmichaelo invivonanoparticlebasedtcellimagingcanpredicttherapyresponsetowardsadoptivetcelltherapyinexperimentalglioma |